Nasdaq: HSICHenry Schein

    Henry Schein Q3 2026 Results: Net Income $119 Million on Revenue of $3.47 Billion

    • US stocks
    • Earnings
    • Health Care
    Stainless steel dental instrument trays holding scalers, probes and forceps on a clinic counter
    Neva79, via Wikimedia Commons (CC0). Illustrative image.

    Henry Schein (Nasdaq: HSIC) reported GAAP revenue of $3.47 billion and GAAP net income of $119.0 million for the third quarter of 2026, and it said on 3 Nov 2026. GAAP diluted EPS was $1.06, and non-GAAP diluted EPS, a company-defined measure, was $1.56.

    Key highlights

    • Revenue (GAAP): $3.47 billion, up 4.0% YoY and 0.4% QoQ
    • Net income (GAAP): $119.0 million, up 17.8% YoY
    • Diluted EPS (GAAP): $1.06, up 26.2% YoY
    • Non-GAAP diluted EPS (company-defined): $1.56, up 13.0% YoY
    • Full-year 2026 non-GAAP diluted EPS guidance (company-defined): $5.50 to $5.56, up from $5.29 to $5.39

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue3,471.03,339.0+4.0%3,458.0+0.4%
    193.0164.0+17.7%171.0+12.9%
    119.0101.0+17.8%94.0+26.6%
    Diluted EPS ($)1.060.84+26.2%0.82+29.3%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 26 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Against the third quarter of 2025, GAAP revenue rose 4.0%, GAAP operating income rose 17.7% and GAAP diluted EPS rose 26.2%. The GAAP net income margin was 3.4% of revenue, against 3.0% a year earlier, 0.4 percentage points higher. The GAAP operating margin was 5.6%, against 4.9%.

    Against the previous quarter, GAAP revenue rose 0.4%, to $3.47 billion from $3.46 billion. GAAP net income rose 26.6%, to $119.0 million from $94.0 million.

    Non-GAAP figures exclude restructuring and amortization costs

    Henry Schein's non-GAAP net income, which it presents as a supplement to GAAP results, was $175 million, against $167 million a year earlier. The company said its non-GAAP measures exclude items such as restructuring and related costs, amortization of acquisition-related assets, changes in contingent consideration, shareholder advisory costs and litigation settlements.

    The company said its $1.56 non-GAAP diluted EPS includes a $0.19 per diluted share net benefit from tariff refunds. Excluding that benefit and the $0.23 per diluted share remeasurement gain in the prior-year quarter, non-GAAP diluted EPS was $1.37, against $1.15, up 19.1%.

    Dental merchandise sales led the growth

    Total net sales were $3.47 billion, up 4.0%. The company said this included 3.1% internal growth and 0.7% from acquisitions. U.S. dental merchandise sales rose 8.6%, which the company said was due primarily to volume from market share gains.

    For the first nine months of 2026, total net sales were $10.3 billion, up 5.6%. GAAP diluted EPS was $2.80, up 15.7%, and non-GAAP diluted EPS was $4.14, up 14.0%.

    Outlook raised for 2026

    The company now expects 2026 non-GAAP diluted EPS of $5.50 to $5.56, up from $5.29 to $5.39. Its total sales growth outlook is unchanged at 4.5% to 5.5%, and it now expects Adjusted EBITDA growth in the high-single-digits, against a mid to high-single-digits range before.

    The company said the guidance includes the third-quarter tariff refund benefit and assumes no significant tariff refunds or remeasurement gains for the rest of 2026. It said targeted, limited growth investments in the fourth quarter will contribute to growth in 2027. The guidance excludes restructuring costs, acquired-intangible amortization, impairments, contingent consideration changes, select implementation costs and litigation settlements.

    The company said it cannot provide a GAAP reconciliation of that guidance without unreasonable effort, as it cannot estimate restructuring and related costs.

    Inference

    Diluted weighted-average shares were 112,538,936 in the quarter, against 121,036,247 a year earlier. The company repurchased about 1.4 million shares for $125 million in the quarter, at an average of $86.67 per share. Year to date it repurchased about 5.7 million shares for $450 million, and about $330 million remained authorized at quarter end.

    The release does not mention a dividend declared or paid in the quarter, or free cash flow.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts